---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063774"
form_type: "8-K/A"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:58:54.884035+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics raises $67.154M in Series A-1 Preferred; restructures warrant tranches

## Summary
- Initially issued 7,500 Series A-1 Preferred shares for $7.5M on Oct 2, 2023.
- Exercised Tranche A warrants: 59,654 additional shares for $59.654M by Nov 14.
- Investors assumed 16,269 unexercised warrants; received new Tranche B and C warrants.
- Outstanding now: 42,846 Tranche B warrants ($42.846M) and 107,115 Tranche C warrants ($107.115M).
- Unexercised Tranche A warrants and remaining Tranche B/C warrants cancelled.

## SEC filing metadata
- accession: 0000950170-23-063774
- form_type: 8-K/A
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017023063774/0000950170-23-063774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017023063774/sabs-20230929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063774
- JSON: https://secwatch.observer/filing/0000950170-23-063774.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.